Cited by 206Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsNeurological Disease Mechanisms and Treatments

IFN-γ Promotes Complement Expression and Attenuates Amyloid Plaque Deposition in Amyloid β Precursor Protein Transgenic Mice

Open access
Chakrabarty, Paramita, Ceballos-Diaz, Carolina, Beccard, Amanda, Janus, Christopher, Dickson, Dennis, Golde, Todd E, Das, Pritam·2010·The Journal of Immunology

Abstract

Reactive gliosis surrounding amyloid β (Aβ) plaques is an early feature of Alzheimer’s disease pathogenesis and has been postulated to represent activation of the innate immune system in an apparently ineffective attempt to clear or neutralize Aβ aggregates. To evaluate the role of IFN-γ–mediated neuroinflammation on the evolution of Aβ pathology in transgenic (Tg) mice, we have expressed murine IFN-γ (mIFN-γ) in the brains of Aβ precursor protein (APP) Tg mice using recombinant adeno-associated virus serotype 1. Expression of mIFN-γ in brains of APP TgCRND8 mice results in robust noncell autonomous activation of microglia and astrocytes, and a concomitant significant suppression of Aβ deposition. In these mice, mIFN-γ expression upregulated multiple glial activation markers, early components of the complement cascade as well as led to infiltration of Ly-6c positive peripheral monocytes but no significant effects on APP levels, APP processing or steady-state Aβ levels were noticed in vivo. Taken together, these results suggest that mIFN-γ expression in the brain suppresses Aβ accumulation through synergistic effects of activated glia and components of the innate immune system that enhance Aβ aggregate phagocytosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.0903382

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Manipulation of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have opposing effects on amyloid and tau pathologies.

    “Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”

    From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [60]

    The Results report that IFN-γ overexpression reduced amyloid plaque burden in APP transgenic mice. The Discussion reports decreased tau pathology in a different IFN-γ mouse study, but says that study did not report plaque burden and cautions against drawing parallels. This paper therefore supports an effect of IFN-γ on amyloid pathology, not the claimed opposing effects on amyloid and tau pathology. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Activated micro/astroglia enhances Aβ phagocytosis.

    “For amyloid pathology, there is data that activated micro/astroglia enhances Aβ phagocytosis [60, 62, 71]”

    From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [60]

    The Results section reports increased uptake of fibrillar Aβ42 by mouse microglia primed with IFN-γ in vitro. This supports the microglial part of the claim, but the cited passages do not show enhanced Aβ phagocytosis by astroglia. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Administration or expression of IFN-γ, TNF, or IL-6 in mouse CNS reduced Aβ deposition.

    “administration or expression of IFN-γ, TNF or IL-6 in the mouse CNS reduced Aβ deposition [48–50]”
  • Increased gliosis induced by brain infusion of lipopolysaccharide or overexpression of interleukin-6 or interferon-γ markedly reduces amyloid plaque burden.

    “For example, increased gliosis induced by brain infusion of lipopolysaccharide (4) or overexpression of the inflammatory cytokine interleukin-6 (5) or interferon-γ (6) markedly reduces amyloid plaque burden.”
  • Mice overexpressing IL-6 or IFN-γ show enhanced microglial phagocytosis of amyloid-beta accompanied by increased complement component mRNA, TNF-α, and other inflammatory mediators.

    “mice overexpressing IL-6 (127) or IFN-γ (128) had enhanced microglial phagocytosis of Aβ accompanied by an increase in complement component mRNA levels, TNF-α, and other inflammatory mediators.”

    From Microglia in Alzheimer's disease (2017) · cites this paper as [128]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chakrabarty, P., Ceballos-Diaz, C., Beccard, A., Janus, C., Dickson, D., Golde, T. E., & Das, P.
Affiliations
  • Mayo Clinic (US)
  • Department of Neuroscience, Mayo Clinic , Jacksonville, FL 32224
  • University of Florida (US)
Venue
The Journal of Immunology
Published
2010-05-01
Volume
184
Issue
9
Pages
5333-5343
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2157079522
Cited by
206
References
71
Citations by year
2026: 2 · 2025: 11 · 2024: 4 · 2023: 10 · 2022: 25 · 2021: 24 · 2020: 15 · 2019: 17 · 2018: 8 · 2017: 12 · 2016: 11 · 2015: 14 · 2014: 13 · 2013: 13 · 2012: 15
FWCI
8.66
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Mayo Clinic
  • American Health Assistance Foundation
  • National Institutes of Health
  • National Institute on Aging (R01 AG18454, P01AG025531, R01AG018454, R01AG029886, R01AG29886, P01AG25531)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
interferon-gamma, amyloid-beta, amyloid plaques, Alzheimer's disease, APP transgenic mice, complement system, reactive gliosis, microglial activation, astrocyte activation, neuroinflammation, innate immunity, AAV gene delivery, phagocytosis, peripheral blood monocytes, TgCRND8 mice
MeSH terms
Dependovirus, Alzheimer Disease, Animals, Astrocytes, Cell Line, Chickens, Complement System Proteins, Disease Models, Animal, Female, Humans, Immunity, Innate, Interferon-gamma, Male, Mice, Inbred C57BL, Mice, Transgenic, Neuroglia, Phagocytosis, Protein Processing, Post-Translational, Down-Regulation, Up-Regulation, Amyloid beta-Protein Precursor, Microglia, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review